Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma

The intravenous administration (IV) of daratumumab sometimes causes an infusion reaction and needs a long infusion time. Recently, a subcutaneous formulation (SC) of daratumumab, which has fewer infusion reactions and shorter administration time, was approved. However, because SC has a fixed dose, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaoka, Kenta, Irie, Kei, Hiramoto, Nobuhiro, Hirabatake, Masaki, Ikesue, Hiroaki, Hashida, Tohru, Shimizu, Tadashi, Ishikawa, Takayuki, Muroi, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560139/
https://www.ncbi.nlm.nih.gov/pubmed/37721661
http://dx.doi.org/10.1007/s10637-023-01392-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560139/
https://www.ncbi.nlm.nih.gov/pubmed/37721661
http://dx.doi.org/10.1007/s10637-023-01392-1

Ejemplares similares